Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting
Aspect Biosystems and Novo Nordisk A/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.